Answers are grounded in this paper and cite their sources.
Shows that co-administration of quercetin and MCC950 reduces inflammation in a demyelination model, indicating a potential therapeutic approach.
• Co-administration of quercetin and MCC950 ameliorates demyelination in the corpus callosum. • Co-administration of quercetin and MCC950 attenuates astrocytes activation in the corpus callosum. • Co-administration of quercetin and MCC950 reduces oxidative stress and inflammation in the corpus callosum.
No takes yet. Share an insight, caveat, or question.
Nourmohammadi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: